ArticleCancer management and research2025
Experiences with Higher-Risk Myelodysplastic Syndromes and Improving Patient-Centered Treatment Decision-Making: A Qualitative Study of Patients, Caregivers, and Providers.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Understanding the evolving role of early palliative care in myelodysplastic syndromes: a 2026 narrative review.Annals of hematology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Research on treatment experiences and decision-making in higher-risk myelodysplastic syndromes (HR-MDS) remains limited, with most studies employing quantitative approaches. This study employed qualitative research methods to further explore patients', caregivers', and providers' experiences with HR-MDS and treatment decision-making. Patients and Methods: Exploratory, qualitative web-based focus groups and interviews were conducted between April-May 2023 amongst US-based patients with HR-MDS, caregivers for a patient with HR-MDS for ≥3 months, and board-certified oncologists and/or hematologists who treated ≥5 patients with HR-MDS in the past year. Recruitment was facilitated by a survey vendor and the MDS Foundation using convenience sampling. De-identified transcripts were analyzed using constant comparative analysis to identify key themes. Results: A total of 8 patients, 6 caregivers, and 18 providers participated. Providers described challenges conveying the HR-MDS diagnosis to patients, while patients and caregivers reported lacking information regarding the condition, prognosis, and available treatment options. Providers discussed the lack of HR-MDS treatment options. Patients and caregivers were primarily concerned with treatment efficacy and ability to improve quality of life. While patients, caregivers, and providers expressed interest in shared decision-making (SDM), implementation of SDM can be influenced by the patient's age, level of education, and health literacy. Treatment barriers included lack of treatment options, insurance coverage, lack of information sharing, and access to treatment centers. High levels of caregiver burden were reported, with caregivers having to sacrifice their social lives, assume financial responsibility, and execute the daily management of the patient. Conclusion: Findings highlight key challenges in HR-MDS including the complexities surrounding HR-MDS education and communication. Patient-centered approaches incorporating cognitively appropriate education and decision aids, and provision of supportive services are needed to improve patient-centered treatment decision-making in HR-MDS. Future research should build upon these findings amongst the broader HR-MDS population and explore practical approaches to facilitate patient-provider communication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.